Bo Zhang

Dr. Bo Zhang

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2013 in Molecular Brain
Verified
Journal Article
Open access
PDF file
NHNorimichi Higurashi
Norimichi Higurashi
TUTaku Uchida
Taku Uchida
CLChristoph Lossin
Christoph Lossin
YMYoshio Misumi
Yoshio Misumi
YOYohei Okada
Yohei Okada
SHShinichi Hirose
Shinichi Hirose
Background: Dravet syndrome is a devastating infantile-onset epilepsy syndrome with cognitive deficits and autistic traits caused by genetic alterations in SCN1A gene encoding the α-subunit of the voltage-gated sodium channel Nav1.1. Disease modeling using patient-derived induced pluripotent stem cells (iPSCs) can be a powerful tool to reproduce this syndrome’s human pathology. However, no such effort has been reported to date. We here report a cellular model for DS that utilizes patient-derived iPSCs. Results: We generated iPSCs from a Dravet syndrome patient with a c.4933C>T substitution in SCN1A, which is predicted to result in truncation in the fourth homologous domain of the protein (p.R1645*). Neurons derived from these iPSCs were primarily GABAergic (>50%), although glutamatergic neurons were observed as a minor population (<1%). Current-clamp analyses revealed significant impairment in action potential generation when strong depolarizing currents were injected. Conclusions: Our results indicate a functional decline in Dravet neurons, especially in the GABAergic subtype, which supports previous findings in murine disease models, where loss-of-function in GABAergic inhibition appears to be a main driver in epileptogenesis. Our data indicate that patient-derived iPSCs may serve as a new and powerful research platform for genetic disorders, including the epilepsies.

7 March 2022 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
SLSimeng Liu
Simeng Liu
YYYanggang Yuan
Yanggang Yuan
YXYi Xue
Yi Xue
YXYing chang Xing
Ying chang Xing
BZBo Zhang
Bo Zhang
Podocytes are a crucial cellular component in maintaining the glomerular filtration barrier, and their injury is the major determinant in the development of albuminuria and diabetic kidney disease (DKD). Podocytes are rich in mitochondria and heavily dependent on them for energy to maintain normal functions. Emerging evidence suggests that mitochondrial dysfunction is a key driver in the pathogenesis of podocyte injury in DKD. Impairment of mitochondrial function results in an energy crisis, oxidative stress, inflammation, and cell death. In this review, we summarize the recent advances in the molecular mechanisms that cause mitochondrial damage and illustrate the impact of mitochondrial injury on podocytes. The related mitochondrial pathways involved in podocyte injury in DKD include mitochondrial dynamics and mitophagy, mitochondrial biogenesis, mitochondrial oxidative phosphorylation and oxidative stress, and mitochondrial protein quality control. Furthermore, we discuss the role of mitochondria-associated membranes (MAMs) formation, which is intimately linked with mitochondrial function in podocytes. Finally, we examine the experimental evidence exploring the targeting of podocyte mitochondrial function for treating DKD and conclude with a discussion of potential directions for future research in the field of mitochondrial dysfunction in podocytes in DKD.

1 October 2004 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
BZBo Zhang
Bo Zhang
PFPing Fan
Ping Fan
ESEiso Shimoji
Eiso Shimoji
HXHuali Xu
Huali Xu
KTKazuma Takeuchi
Kazuma Takeuchi
KSKeijiro Saku
Keijiro Saku
Background— Inhibition of cholesteryl ester transfer protein (CETP) is an efficient way to increase high-density lipoprotein (HDL) levels in humans. We investigated the effects of the inhibition of CETP activity by a CETP inhibitor, JTT-705, on the function and composition of HDL particles. Methods and Results— Japanese white rabbits were fed either normal rabbit chow LRC-4 (n=10) or a food admixture of LRC-4 and 0.75% JTT-705 (n=10) for 7 months. JTT-705 significantly inhibited CETP activities, increased HDL cholesterol (HDL-C) levels and the ratio of HDL 2 -C/HDL 3 -C, and decreased the fractional esterification rate of cholesterol in HDL, indicating preferentially increased large HDL particles. Treatment with JTT-705 increased all of the 3 charge-based HDL subfractions as determined by capillary isotachophoresis: fast-migrating, intermediate-migrating, and slow-migrating HDL. The percentage of slow HDL, ie, apolipoprotein E (apoE)-containing HDL and levels of apoE in HDL fraction, was also increased. JTT-705 treatment increased serum paraoxonase activity and HDL-associated platelet-activating factor acetylhydrolase activity, but decreased the plasma lysophosphatidylcholine concentration. Conclusion— Inhibition of CETP activity by JTT-705 not only increased the quantity of HDL, including HDL-C levels and charge-based HDL subfractions, but also favorably affected the size distribution of HDL subpopulations and the apolipoprotein and enzyme composition of HDL in rabbits.

11 June 2019 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
OGon behalf of the Japan TGCV study group
on behalf of the Japan TGCV study group
MLMing Li
Ming Li
KHKen-Ichi Hirano
Ken-Ichi Hirano
YIYoshihiko Ikeda
Yoshihiko Ikeda
MHMasahiro Higashi
Masahiro Higashi
KKKunihisa Kobayashi
Kunihisa Kobayashi
Triglyceride deposit cardiomyovasculopathy (TGCV) is a phenotype primarily reported in patients carrying genetic mutations in PNPLA2 encoding adipose triglyceride lipase (ATGL) which releases long chain fatty acid (LCFA) as a major energy source by the intracellular TG hydrolysis. These patients suffered from intractable heart failure requiring cardiac transplantation. Moreover, we identified TGCV patients without PNPLA2 mutations based on pathological and clinical studies. We provided the diagnostic criteria, in which TGCV with and without PNPLA2 mutations were designated as primary TGCV (P-TGCV) and idiopathic TGCV (I-TGCV), respectively. We hereby report clinical profiles of TGCV patients. Between 2014 and 2018, 7 P-TGCV and 18 I-TGCV Japanese patients have been registered in the International Registry. Patients with I-TGCV, of which etiologies and causes are not known yet, suffered from adult-onset severe heart disease, including heart failure and coronary artery disease, associated with a marked reduction in ATGL activity and myocardial washout rate of LCFA tracer, as similar to those with P-TGCV. The present first registry-based study showed that TGCV is an intractable, at least at the moment, and heterogeneous cardiovascular disorder.

1 October 2020 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
SDSuyan Duan
Suyan Duan
JCJiajia Chen
Jiajia Chen
LWLin Wu
Lin Wu
GNGuangyan Nie
Guangyan Nie
LSLianqin Sun
Lianqin Sun
YYYanggang Yuan
Yanggang Yuan

1 April 2021 in International Immunopharmacology
Verified
Journal Article
Closed access
SDSuyan Duan
Suyan Duan
LSLianqin Sun
Lianqin Sun
CZChengning Zhang
Chengning Zhang
LWLin Wu
Lin Wu
GNGuangyan Nie
Guangyan Nie
YYYanggang Yuan
Yanggang Yuan